Opinion

Video

First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

Panelists discuss how luspatercept’s mechanism of action, its first-line indication for patients with lower-risk MDS with ring sideroblasts, and the results of the COMMANDS trial support its use as an effective alternative to traditional erythropoiesis-stimulating agents, potentially changing the treatment landscape for transfusion-dependent patients with MDS.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please describe the mechanism of luspatercept and luspatercept’s indication in the first-line setting
    • Please summarize the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
    • Please comment on the study design, pertinent patient characteristics, and primary/secondary end points.
    • What are your impressions of the recently published full analysis of the COMMANDS trial?
    • What are the clinical implications of this study?
    • What are your impressions and interpretation of luspatercept’s impact on the various hematopoietic stem cell lineages (erythroid, neutrophil, platelet)? How do these data impact your day-to-day practice?
    • Resource links: Luspatercept’s impact on erythroid, neutrophil, and platelet lineages. Garcia-Manero G, et al. EHA 2024. Abstract P780 & COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024)

    Related Content